UB
RXRX icon

UMB Bank’s Recursion Pharmaceuticals RXRX Stock Holding History

UMB Bank’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4
Closed – – 1815
2022
Q3 		$0 Buy
+4
New +$41 ﹤0.01% 1935

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

UMB Bank's RXRX Position: Q4 2022 in Review

UMB Bank sold out of Recursion Pharmaceuticals (RXRX) in Q4 2022, closing a stake of 4 shares.

UMB Bank first reported a position in RXRX in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 144 funds tracked by Wall St. Rank hold RXRX as of Q4 2022.

  • UMB Bank reported no remaining Recursion Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • UMB Bank sold 4 Recursion Pharmaceuticals shares in Q4 2022.
  • UMB Bank first reported a position in Recursion Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • UMB Bank's Recursion Pharmaceuticals position peaked at $0 in Q3 2022.
  • 144 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2022.

Based on UMB Bank's 13F filing for Q4 2022, filed 10 Jan 2023.